Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 08 2022
Historique:
received: 10 09 2021
accepted: 06 08 2022
entrez: 19 8 2022
pubmed: 20 8 2022
medline: 24 8 2022
Statut: epublish

Résumé

The biological determinants of the response to immune checkpoint blockade (ICB) in cancer remain incompletely understood. Little is known about dynamic biological events that underpin therapeutic efficacy due to the inability to frequently sample tumours in patients. Here, we map the transcriptional profiles of 144 responding and non-responding tumours within two mouse models at four time points during ICB. We find that responding tumours display on/fast-off kinetics of type-I-interferon (IFN) signaling. Phenocopying of this kinetics using time-dependent sequential dosing of recombinant IFNs and neutralizing antibodies markedly improves ICB efficacy, but only when IFNβ is targeted, not IFNα. We identify Ly6C

Identifiants

pubmed: 35986006
doi: 10.1038/s41467-022-32567-8
pii: 10.1038/s41467-022-32567-8
pmc: PMC9390963
doi:

Substances chimiques

Interferon Type I 0
Interferon-alpha 0
Interferon-beta 77238-31-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4895

Informations de copyright

© 2022. The Author(s).

Références

Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
Clin Cancer Res. 2019 Feb 15;25(4):1130-1132
pubmed: 30291135
Science. 2001 Jul 13;293(5528):240-5
pubmed: 11452112
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nat Immunol. 2006 Mar;7(3):311-7
pubmed: 16462739
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316010
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Bioinformatics. 2014 Mar 15;30(6):801-7
pubmed: 22321699
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Sci Rep. 2015 Jul 21;5:12298
pubmed: 26193793
J Bioinform Comput Biol. 2005 Aug;3(4):965-88
pubmed: 16078370
Nat Methods. 2017 Jul;14(7):687-690
pubmed: 28581496
Science. 2013 Apr 12;340(6129):207-11
pubmed: 23580529
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
BMC Genomics. 2013 Sep 20;14:632
pubmed: 24053356
Nat Commun. 2017 Oct 19;8(1):1050
pubmed: 29051489
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Nat Commun. 2021 Nov 25;12(1):6876
pubmed: 34824236
Nat Rev Drug Discov. 2016 Aug;15(8):551-67
pubmed: 27020098
Lancet Oncol. 2017 Aug;18(8):981
pubmed: 28759366
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Brief Bioinform. 2012 Sep;13(5):627-44
pubmed: 22155641
Cell. 2018 Nov 1;175(4):984-997.e24
pubmed: 30388455
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Science. 2013 Apr 12;340(6129):202-7
pubmed: 23580528
Oncoimmunology. 2018 Aug 1;7(9):e1462431
pubmed: 30228932
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16072-16082
pubmed: 32571915
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cell Rep. 2020 Jul 7;32(1):107873
pubmed: 32640238
Nat Rev Drug Discov. 2017 Apr;16(4):264-272
pubmed: 28057932
Genome Biol. 2020 Jun 2;21(1):130
pubmed: 32487174
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23684-23694
pubmed: 32907939
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6
pubmed: 14681465
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618661
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nat Protoc. 2020 May;15(5):1628-1648
pubmed: 32238953
Cell. 2017 Jan 26;168(3):542
pubmed: 28129544
Nat Med. 2021 May;27(5):820-832
pubmed: 33958794
Science. 2018 May 18;360(6390):758-763
pubmed: 29622724
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Genome Res. 2019 Apr;29(4):697-709
pubmed: 30858345
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Nat Commun. 2020 Apr 14;11(1):1801
pubmed: 32286271
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Cell Host Microbe. 2015 May 13;17(5):653-61
pubmed: 25974304
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Vaccine. 2006 Jun 12;24(24):5119-32
pubmed: 16704888
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20416-21
pubmed: 19088190
Cancer Cell. 2021 May 10;39(5):649-661.e5
pubmed: 33711272
PLoS One. 2010 Sep 28;5(9):
pubmed: 20927193
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Cell Res. 2019 Oct;29(10):846-861
pubmed: 31481761
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Nucleic Acids Res. 2018 Jan 4;46(D1):D260-D266
pubmed: 29140473
Genome Biol. 2018 Apr 12;19(1):53
pubmed: 29650040
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Immunity. 2014 Jan 16;40(1):13-24
pubmed: 24439265
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
Nat Methods. 2012 Jul 15;9(8):796-804
pubmed: 22796662
Cell Rep. 2016 Apr 5;15(1):171-180
pubmed: 27052162
PLoS One. 2013 Apr 23;8(4):e61895
pubmed: 23626745
Nucleic Acids Res. 2015 Jul 1;43(W1):W589-98
pubmed: 25897122
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer Res. 1999 Mar 1;59(5):1071-9
pubmed: 10070965
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32780802
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cancer Immunol Res. 2017 Jan;5(1):29-41
pubmed: 27923825
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Nat Methods. 2016 Mar;13(3):241-4
pubmed: 26780092
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Immunol Lett. 2018 Mar;195:45-54
pubmed: 29106987

Auteurs

Rachael M Zemek (RM)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia.
Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.

Wee Loong Chin (WL)

Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.
Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia.
School of Medicine, University of Western Australia, Crawley, WA, 6009, Australia.

Vanessa S Fear (VS)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia.
Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.

Ben Wylie (B)

Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.

Thomas H Casey (TH)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia.

Cath Forbes (C)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia.
Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.

Caitlin M Tilsed (CM)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia.

Louis Boon (L)

Polpharma Biologics, Yalelaan 46, Alexander Numan Building, 3584 CM, Utrecht, The Netherlands.

Belinda B Guo (BB)

Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA, 6009, Australia.

Anthony Bosco (A)

Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia.

Alistair R R Forrest (ARR)

Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA, 6009, Australia.

Michael J Millward (MJ)

Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia.
School of Medicine, University of Western Australia, Crawley, WA, 6009, Australia.

Anna K Nowak (AK)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia.
School of Medicine, University of Western Australia, Crawley, WA, 6009, Australia.

Richard A Lake (RA)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia.

Timo Lassmann (T)

Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia. timo.lassmann@telethonkids.org.au.

W Joost Lesterhuis (WJ)

National Centre for Asbestos Related Diseases, Nedlands, WA, 6009, Australia. willem.lesterhuis@uwa.edu.au.
School of Biomedical Sciences, University of Western Australia, Crawley, WA, 6009, Australia. willem.lesterhuis@uwa.edu.au.
Telethon Kids Institute, University of Western Australia, Nedlands, WA, 6009, Australia. willem.lesterhuis@uwa.edu.au.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH